AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 132 min read$CC

Dignam Denise purchased $51K of CC

Dignam Denise (Chief Executive Officer) purchased 3,378 shares of Chemours Co (CC) at $14.95 on 2026-08-11.

Original reporting
SEC EDGAR · Dignam Denise
Published Aug 13, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CC
Bullish
medium confidence
Mentioned
$CC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCBullishLow
01

Why it matters

This is a primary-source insider buy, which can modestly support sentiment, but it does not introduce new guidance, earnings, contracts, or regulatory developments.

02

Market read

Traders may note the CEO buying as a small bullish signal, but the lack of fundamental updates limits tradable impact.

03

What to watch

The article states no 10b5-1 plan and provides trade price and share count, but it does not indicate whether this is part of a broader pattern of buys/sells or whether other insiders are acting similarly.

Relevance 4/10Novelty 5/10Timing: Form 4 filed Aug 13, covering an Aug 11 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Chemours (CC), reporting an open-market purchase by the CEO.

Company-level read

Ticker impact

$CCBullishMedium confidence
Context

Chemours CEO Dignam Denise bought 3,378 shares in an open-market transaction at $14.95/share, disclosed via Form 4 filed Aug 13.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no new company fundamentals, and the trade size is not large enough to imply a major re-rating by itself.

Market effects

Sector

Minimal; insider buying in one chemical company rarely changes sector expectations without accompanying operational or guidance news.

Regional

Minimal; Chemours is US-listed and the disclosure is company-specific.

Global

Minimal; no cross-border deal, regulation, or macro linkage is described.

Counterpoint

What could challenge this read

Insider purchases can be routine (tax planning, diversification, or pre-planned liquidity needs) and do not necessarily reflect a change in near-term fundamentals.

Key entities

  • issuer
    Chemours Co

    US-listed company whose CEO insider purchase is disclosed on Form 4.

  • insider
    Dignam Denise

    Chief Executive Officer and reporting person who purchased shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CC insider trading history →

Related articles

AUG 8
$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after its Q2 earnings. The company reported slight revenue decline and adjusted EPS of $0.42, down 31% year over year, meeting expectations. Management cited lower Optane refrigerant sales due to supply-chain inventory and the wind-down of the SPS Capstone business. Full-year growth guidance remains 1% to 5%.

aol.com6 min
AUG 5
$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after the company reported Q2 results. Revenue edged down and adjusted EPS fell 31% to $0.42, missing expectations. Lower Optane refrigerant sales and the prior wind-down of the SPS Capstone business weighed on results. Chemours still forecasts full-year growth of 1% to 5%.

yahoo.com4 min
AUG 4
$CCMedAI 8/10

The Chemours Company Reports Second Quarter Results

Chemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.

prnewswire.com7 min
AUG 4
$CCMed

Chemours Co (CC): Results of Operations and Financial Condition

Chemours Co (CC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 The Chemours Company Reports Second Quarter Results Wilmington, Del., August 4, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Special

SEC EDGAR 8-K6 min
JUL 9
$MMMHighAI 9/10

New York sues 3M, DuPont and other chemical companies over PFAS pollution By Investing.com

New York Attorney General Letitia James sued 3M, DuPont, Chemours, Corteva and EIDP over alleged PFAS (“forever chemicals”) contamination. The complaint says the firms knew since decades-old research that PFAS were toxic but concealed risks, continued selling PFAS products, and allegedly misled consumers. New York seeks cleanup funding, consumer warnings, advertising changes, and damages and penalties.

investing.com3 min